Future strategies in the diagnosis, staging and treatment of bladder cancer
- 1 September 2003
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Urology
- Vol. 13 (5), 389-395
- https://doi.org/10.1097/00042307-200309000-00006
Abstract
In this review new modalities in the diagnosis, staging and treatment of superficial and invasive bladder cancer are reviewed. Urinary markers still cannot replace cystoscopy in diagnosing bladder cancer. However, DNA micro-array has shown promise for diagnosis. In the treatment of superficial bladder cancer, valrubicin, pirarubicin and gemcitabine are novelties. Furthermore, a combination therapy of hyperthermia and mitomycin-C as well as photodynamic therapy seem to be safe and effective new treatment modalities. For staging, computed tomography, magnetic resonance imaging and the positron emission tomography scan are limited. Nevertheless, the pT-category, pN-category and the number of lymph nodes removed affect survival significantly and are thus useful for staging and prognosis. This indicates a need for a standardized lymph node dissection in cystectomy patients. In the treatment of invasive bladder cancer, prostate-sparing cystectomy shows promising potency and continence results. In advanced disease, gemcitabine-cisplatin is a valuable alternative to methotrexate-vinblastine-doxorubicin-cisplatin with fewer side-effects. Finally, radical radiotherapy should be considered a valid treatment in patients with invasive bladder cancer.Keywords
This publication has 34 references indexed in Scilit:
- Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladderEuropean Journal of Surgical Oncology, 2003
- Use of High-Throughput DNA Microarrays to Identify Biomarkers for Bladder CancerClinical Chemistry, 2003
- Identifying distinct classes of bladder carcinoma using microarraysNature Genetics, 2002
- Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analysesThe Journal of Pathology, 2002
- Role of 5‐aminolevulinic acid in the detection of urothelial premalignant lesionsCancer, 2002
- La cystoscopie en fluorescence dans le cancer de la vessie, quel avenir ?Annales d'Urologie, 2002
- Outcome of radical cystectomy for bladder cancer according to the disease type at presentationBJU International, 2002
- What we could do now: molecular pathology of bladder cancerMolecular Pathology, 2001
- p53 Immunohistochemistry as a Prognostic Marker in Bladder CancerEuropean Urology, 2000
- The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trialBJU International, 1994